Were Cheryl Gault’s Rapport Therapeutics (RAPP) share sales under a Rule 10b5-1 plan?

Yes. The Form 4 notes that these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. Such plans pre-schedule trades, making their timing more routine rather than discretionary market timing decisions.

Rapport Therapeutics (RAPP) COO sells 10,000 shares in pre-set 10b5-1 trades

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Rapport Therapeutics Chief Operating Officer Cheryl Gault reported open-market sales totaling 10,000 shares of common stock on June 30, 2026. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan at weighted average prices between about $40 and $43 per share.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($415,798)

Net Sell 4 txns

Insider Gault Cheryl

Role Chief Operating Officer

Sold 10,000 shs ($416K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,900	$40.0914	$76K
Sale	Common Stock	3,792	$41.3934	$157K
Sale	Common Stock	3,308	$42.1722	$140K
Sale	Common Stock	1,000	$43.1547	$43K

Holdings After Transaction: Common Stock — 158,014 shares (Direct, null)

Footnotes (1)

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.61 to $40.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.80 to $41.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.81 to $42.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.81 to $43.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Key Figures

Shares sold: 10,000 shares Weighted avg price lot 1: $40.0914/share Weighted avg price lot 2: $41.3934/share +5 more

8 metrics

Shares sold 10,000 shares Total common stock sold by COO on June 30, 2026

Weighted avg price lot 1 $40.0914/share Open-market sale of 1,900 shares

Weighted avg price lot 2 $41.3934/share Open-market sale of 3,792 shares

Weighted avg price lot 3 $42.1722/share Open-market sale of 3,308 shares

Weighted avg price lot 4 $43.1547/share Open-market sale of 1,000 shares

Price range low $39.61/share Lowest trade price in reported ranges

Price range high $43.65/share Highest trade price in reported ranges

Net buy/sell shares -10,000 shares Transaction summary net-sell for this Form 4

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

net-sell financial

"netBuySellDirection": "net-sell""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:10 PM Accepted by SEC EDGAR 07/01/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gault Cheryl

(Last)

(First)

(Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/30/2026		S⁽¹⁾		1,900	D	$40.0914⁽²⁾	158,014	D
Common Stock	06/30/2026		S⁽¹⁾		3,792	D	$41.3934⁽³⁾	154,222	D
Common Stock	06/30/2026		S⁽¹⁾		3,308	D	$42.1722⁽⁴⁾	150,914	D
Common Stock	06/30/2026		S⁽¹⁾		1,000	D	$43.1547⁽⁵⁾	149,914	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.61 to $40.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.80 to $41.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.81 to $42.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.81 to $43.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Rapport Therapeutics (RAPP) report for Cheryl Gault?

Rapport Therapeutics reported that Chief Operating Officer Cheryl Gault sold 10,000 shares of common stock. The sales were disclosed on a Form 4 and executed as open-market transactions under a pre-arranged Rule 10b5-1 trading plan.

How many Rapport Therapeutics (RAPP) shares did Cheryl Gault sell and on what date?

Cheryl Gault sold a total of 10,000 shares of Rapport Therapeutics common stock. The sales took place on June 30, 2026, in multiple open-market transactions as reflected across four line items in the Form 4 filing.

At what prices did Cheryl Gault sell Rapport Therapeutics (RAPP) shares?

The reported weighted average sale prices ranged from $40.0914 to $43.1547 per share. Footnotes explain that individual trades occurred in ranges between $39.61 and $43.65, with detailed trade-level data available on request from the issuer or SEC staff.

What type of transaction code is shown for Cheryl Gault’s Rapport Therapeutics (RAPP) trades?

Each transaction is coded “S,” indicating a sale in an open-market or private transaction. The filing further describes the action as open-market sales of common stock, consistent with routine insider share dispositions reported to the SEC.

How many total Rapport Therapeutics (RAPP) shares did the Form 4 show as net sold?

The transaction summary shows a net sale of 10,000 shares. It reports four sale transactions totaling 10,000 shares sold, zero purchases, and a net buy/sell direction categorized as “net-sell” for this Form 4 reporting period.